+
For instructor materials including Power Points, Answers to Clinical Encounter Questions, please contact [email protected].
++
Content Update
July 02, 2025
Ensartinib Approved for Non-Small Cell Lung Cancer With an ALK fusion: The kinase inhibitor ensartinib is approved for advanced or metastatic non-small cell lung cancer (NSCLC) that is positive for an anaplastic lymphoma kinase (ALK) fusion protein in patients who have not previously received an ALK inhibitor. Ensartinib was compared to crizotinib, another ALK inhibitor, in an open label randomized phase 3 trial in patients with advanced, recurrent, or metastatic ALK mutated NSCLC. The trial demonstrated median progression-free survival (PFS) was significantly longer with ensartinib than with crizotinib, 25.8 months vs 12.7 months (hazard ratio of 0.51 [95% CI, 0.35–0.72]; log-rank P < .001). The intracranial response rate was 63.6% with ensartinib vs 21.1% with crizotinib. Common adverse effects included rash, elevated liver function tests and itching.
++
Content Update
December 20, 2024
Zenocutuzumab-zbco Approved for Non-Small Cell Lung Cancer and Pancreas Cancer with an NRG fusion: The bispecific HER2- and HER3-directed antibody zenocutuzumab-zbco is approved for advanced metastatic non-small cell lung cancer (NSCLC) and pancreas cancer that is positive for an NRG fusion that has progressed after at least one prior therapy. Zenocutuzumab was evaluated in the open label phase 2 eNRGy trial in patients with advanced, previously treated solid tumors harboring an NRG fusion. The trial demonstrated an overall response rate (ORR) of 33% (95% CI, 22%-46%) and a median duration of response (DOR) of 7.4 months (95% CI, 4.0-16.6) in patients with lung cancer and an ORR of 40% (95% CI, 23%-59%), while the DOR ranged from 3.7 months to 16.6 months in patients with pancreas cancer. Common adverse effects included diarrhea, abdominal pain and edema.
++
Content Update
December 20, 2024
Lazertinib Approved for EGFR Mutated Non-Small Cell Lung Cancer: The kinase inhibitor lazertinib is approved in combination with amivantamab for patients with newly diagnosed non-small cell lung cancer (NSCLC) that is positive for EGFR exon 19 deletion or exon 21 L858R substitution mutations. The combination was evaluated in an open label phase 3 trial, enrolling a total of 1074 adult patients and comparing the combination of amivantamab and lazertinib to osimertinib or lazertinib. The median progression-free survival was significantly longer in the amivantamab and lazertinib group compared to the osimertinib group (23.7 vs. 16.6 months; hazard ratio for disease progression or death, 0.70; 95% confidence interval [CI], 0.58 to 0.85; P < 0.001). Common adverse events included paronychia and rash.
++
LEARNING OBJECTIVES
Upon completion of the chapter, the reader will be able to:
Identify major risk factors for the development of lung cancer.
Explain the pathologic progression of lung cancer and its relationship with signs and symptoms of the disease.
Make appropriate recommendations for screening and preventive measures in high-risk patients.
Understand staging of lung cancer patients and how it influences treatment decisions.
...